Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DNLI 
Denali Therapeutics Inc (DNLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: DNLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.6
1 Year Target Price $31.6
| 15 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.53% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.56B USD | Price to earnings Ratio - | 1Y Target Price 31.6 |
Price to earnings Ratio - | 1Y Target Price 31.6 | ||
Volume (30-day avg) 19 | Beta 1.13 | 52 Weeks Range 10.57 - 26.18 | Updated Date 11/16/2025 |
52 Weeks Range 10.57 - 26.18 | Updated Date 11/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.7463 | Actual -0.74 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.29% | Return on Equity (TTM) -44.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1753982367 | Price to Sales(TTM) 3643.65 |
Enterprise Value 1753982367 | Price to Sales(TTM) 3643.65 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 146661833 | Shares Floating 132495767 |
Shares Outstanding 146661833 | Shares Floating 132495767 | ||
Percent Insiders 9.8 | Percent Institutions 101.34 |
Upturn AI SWOT
Denali Therapeutics Inc
Company Overview
History and Background
Denali Therapeutics Inc. was founded in 2015 and is focused on developing therapies for neurodegenerative diseases. It went public in 2017. Key milestones include strategic partnerships and clinical trial advancements.
Core Business Areas
- Discovery and Development: Focuses on discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, ALS, and others.
Leadership and Structure
The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is centered around research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Takeda Collaboration (TAK-981): A small molecule inhibitor of the enzyme USP18, developed in collaboration with Takeda. USP18 regulates interferon signaling, which is relevant to neuroinflammation. Its in Phase 1 trials. Competitors are other companies focusing on neuroinflammation like Annexon Biosciences (ANNX).
- SAR443820 (DNL788): A small molecule RIPK1 inhibitor being co-developed with Sanofi. RIPK1 is a key signaling protein involved in inflammation and cell death. It has demonstrated efficacy in clinical trials, and is currently in phase 3 clinical trials. Major competitors are other companies like Kiniska (KNSA) developing other inflammation treatments.
Market Dynamics
Industry Overview
The industry is characterized by high unmet medical needs, intense competition, and significant regulatory hurdles.
Positioning
Denali is positioned as a leader in developing therapies for neurodegenerative diseases, leveraging its expertise in blood-brain barrier (BBB) technology.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is estimated to be in the tens of billions of dollars annually. Denali is positioned to capture a portion of this market through its pipeline of novel therapeutics.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise
- Proprietary blood-brain barrier (BBB) technology
- Strategic partnerships with large pharmaceutical companies
- Diverse pipeline of therapeutic candidates
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- No approved products
Opportunities
- Expansion of pipeline through internal research and development
- Acquisition or licensing of complementary technologies
- Accelerated regulatory approval pathways
- Growing demand for neurodegenerative disease therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other therapies
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- VRTX
- ABBV
Competitive Landscape
Denali has a competitive advantage in BBB technology. However, it faces competition from larger companies with more resources. Denali's reliance on partnerships can be a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expanding pipeline and partnerships.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary but generally project revenue growth in the coming years.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding its research pipeline.
Summary
Denali Therapeutics shows promise through its BBB technology and strategic partnerships, focusing on neurodegenerative diseases. Success depends on clinical trial outcomes and effective resource management. High R&D costs and competition pose potential challenges, impacting shareholder value and long-term sustainability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 517 | |
Full time employees 517 | |||
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.